Zacks: Brokerages Anticipate Express Scripts Holding (ESRX) Will Announce Quarterly Sales of $25.12 Billion

Analysts expect Express Scripts Holding (NASDAQ:ESRX) to report $25.12 billion in sales for the current quarter, according to Zacks. Twelve analysts have issued estimates for Express Scripts’ earnings, with the lowest sales estimate coming in at $24.54 billion and the highest estimate coming in at $25.54 billion. Express Scripts posted sales of $24.86 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1%. The business is scheduled to announce its next earnings report after the market closes on Tuesday, February 27th.

On average, analysts expect that Express Scripts will report full-year sales of $25.12 billion for the current year, with estimates ranging from $99.22 billion to $100.51 billion. For the next fiscal year, analysts anticipate that the company will post sales of $100.60 billion per share, with estimates ranging from $99.93 billion to $101.33 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Express Scripts.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The firm had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. During the same quarter in the prior year, the company posted $1.74 earnings per share. Express Scripts’s quarterly revenue was down 2.9% on a year-over-year basis.

A number of research analysts recently weighed in on the company. SunTrust Banks reaffirmed a “buy” rating and set a $95.00 price objective on shares of Express Scripts in a report on Friday, January 12th. Robert W. Baird reiterated a “buy” rating and set a $92.00 target price (up from $81.00) on shares of Express Scripts in a research report on Tuesday, January 9th. Evercore ISI assumed coverage on Express Scripts in a research report on Thursday, January 4th. They set an “in-line” rating and a $78.00 target price on the stock. BidaskClub upgraded Express Scripts from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 22nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Express Scripts in a research report on Thursday, December 21st. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $77.09.

In other news, VP Phyllis S. Anderson sold 643 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $62.37, for a total value of $40,103.91. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Christine Houston sold 10,104 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $70.08, for a total value of $708,088.32. Following the completion of the sale, the vice president now owns 87,400 shares in the company, valued at $6,124,992. The disclosure for this sale can be found here. Insiders sold 17,644 shares of company stock worth $1,289,609 over the last 90 days. Company insiders own 0.68% of the company’s stock.

Several large investors have recently modified their holdings of the company. Bank of Nova Scotia Trust Co. purchased a new position in Express Scripts during the third quarter worth about $120,000. Monroe Bank & Trust MI lifted its position in Express Scripts by 74.8% during the third quarter. Monroe Bank & Trust MI now owns 2,266 shares of the company’s stock worth $156,000 after buying an additional 970 shares during the period. Capstone Investment Advisors Netherlands B.V. lifted its position in Express Scripts by 49.3% during the second quarter. Capstone Investment Advisors Netherlands B.V. now owns 2,797 shares of the company’s stock worth $179,000 after buying an additional 924 shares during the period. Alpha Windward LLC lifted its position in Express Scripts by 35.9% during the fourth quarter. Alpha Windward LLC now owns 2,981 shares of the company’s stock worth $223,000 after buying an additional 787 shares during the period. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in Express Scripts during the third quarter worth about $193,000. Institutional investors and hedge funds own 88.21% of the company’s stock.

Express Scripts (NASDAQ ESRX) opened at $80.22 on Friday. Express Scripts has a twelve month low of $55.80 and a twelve month high of $81.75. The firm has a market capitalization of $45,434.44, a price-to-earnings ratio of 11.73, a P/E/G ratio of 0.89 and a beta of 0.87. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86.

Express Scripts announced that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that authorizes the company to repurchase 45,000,000 outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

WARNING: This report was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/12/zacks-brokerages-anticipate-express-scripts-holding-esrx-will-announce-quarterly-sales-of-25-12-billion-updated-updated-updated.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Get a free copy of the Zacks research report on Express Scripts (ESRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply